<DOC>
	<DOC>NCT00814515</DOC>
	<brief_summary>A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehicle in Patients with Moderate to Severe Dry Eye Syndrome</brief_summary>
	<brief_title>Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Males or females 18 years of age or greater. At baseline, moderate to severe dry eye condition persisting despite conventional management. Presence or history of any systemic or ocular disorder or condition, including ocular surgery, trauma or disease that could possibly interfere with the interpretation of study results. Any relevant ocular anomaly interfering with the ocular surface, including post radiation keratitis, StevensJohnson syndrome, corneal ulcer history or concomitant corneal ulcer of infectious origin, etc. Any other ocular diseases requiring topical ocular treatment during the study period. Patient who has participated in a clinical trial with a new active substance during the past month before study entry. Participation in another clinical study at the same time as the present study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Moderate</keyword>
	<keyword>Severe</keyword>
	<keyword>Dry</keyword>
	<keyword>Eye</keyword>
	<keyword>Ciclosporin</keyword>
	<keyword>Cyclosporine</keyword>
</DOC>